# EDGAR Filing Document

**Accession Number:** 0001941029
**File Stem:** 0001213900-26-020807
**Filing Date:** 2026-2
**Character Count:** 16889
**Document Hash:** 213ac866529d7b5f7aca5d658eac5524
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-020807.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001213900-26-020807

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 18

**CONFORMED PERIOD OF REPORT**: 20260220

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Advanced Biomed Inc.
- **CENTRAL INDEX KEY:** 0001941029
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42548
- **FILM NUMBER:** 26689397

**BUSINESS ADDRESS:**
- **STREET 1:** 401 RYLAND ST
- **STREET 2:** STE 200-A
- **CITY:** RENO
- **STATE:** NV
- **ZIP:** 89502
- **BUSINESS PHONE:** 86-21-20510823

**MAIL ADDRESS:**
- **STREET 1:** 401 RYLAND ST
- **STREET 2:** STE 200-A
- **CITY:** RENO
- **STATE:** NV
- **ZIP:** 89502

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**February 20, 2026**

Date of Report (Date of earliest event reported)

**Advanced Biomed Inc.**

(Exact name of Company as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-42548** | **87-2177170** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of Incorporation) |  | Identification Number) |

---

**No. 689-85 Xiaodong Road, Yongkang District**

**Tainan City, Taiwan**

(Address of principal executive offices)

**886-6-3121716**

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | ADVB | The Nasdaq Stock Market LLC |

---

**Item 3.03 Material Modifications to Rights of Security Holders.**

To the extent required by Item 3.03, the disclosure set forth in Item 5.03 is incorporated herein by reference.

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On February 3, 2026, Advanced Biomed Inc. (the "Company") filed with the Secretary of State of the State of Nevada an amendment (the "Certificate of Amendment") to its amended and restated certificate of incorporation, as amended (the "Certificate of Incorporation"), to effect a reverse stock split of the Company's common stock, par value $0.001 per share (the "Common Stock"), at a ratio of 1-for-20 (the "Reverse Stock Split"). The Company's Common Stock began trading on a post-split basis at the open of trading on The Nasdaq Capital Market on February 20, 2026 (the "Effective Time").

At the Effective Time, every twenty (20) shares of the Company's issued and outstanding Common Stock were automatically converted into one (1) share of Common Stock, without any change to the par value per share. No change was made to the number of shares of Common Stock authorized under the Certificate of Incorporation. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders of record who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly divisible by the Reverse Stock Split ratio were automatically entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share. With respect to outstanding shares of Common Stock held in "street name" through a bank, broker or other nominee, fractional shares were rounded up at the participant level. No cash was paid in lieu of fractional shares.

Following the Reverse Stock Split, the shares of Common Stock continue to trade on The Nasdaq Capital Market under the symbol "ADVB." The new CUSIP number for the Common Stock following the Reverse Stock Split is 00752P203.

The foregoing summary of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 8.01 Other Information.**

On February 18, 2026, the Company issued a press release announcing the Reverse Stock Split. The press release is filed as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statement and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1 | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Advanced Biomed Inc.](ea027844801ex33-1.htm) |
| 99.1 | [Press Release issued by Advanced Biomed Inc., dated February 18, 2026.](ea027844801ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Advanced Biomed Inc.** | **Advanced Biomed Inc.** |
| Date: February 26, 2026 | By: | /s/ Yi Lu |
|  |  | Yi Lu |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Advanced Biomed Inc. Announces 1 for 20 Share Consolidation**

Tainan City, Taiwan, — February 18, 2026 — Advanced Biomed Inc. (Nasdaq: ADVB) (the "Company" or "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced a reverse stock split of the Company's issued and outstanding common stock at a ratio of 1 for 20 shares (the "Reverse Split"), which will take effect at the open of The Nasdaq Stock Market ("Nasdaq") on February 20, 2026.

In accordance with Section 78.320.2 of the Nevada Revised Statutes, on January 12, 2026, the holders of a majority of the outstanding voting power of the Company approved by written consent a reverse stock split of the Company's issued and outstanding shares of common stock, at a ratio of not less than 1 for 2 and not more than 1 for 100 shares, with the final ratio and timing of implementation to be determined by the board in its sole discretion, and authorized the board to effect such reverse stock split at any time thereafter. On January 30, 2026, the board approved implementation of the reverse stock split at a ratio of 1 for 20 shares.

The objective of the reverse split is to enable the Company to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed on The Nasdaq Capital Market to evidence a minimum bid price of $1.00 per share.

Upon the open of trading on February 20, 2026, the Company's common stock will begin trading on a reverse split-adjusted basis, under the same symbol "ADVB" but under a new CUSIP number, 00752P203.

As a result of the reverse split, each 20 shares of common stock with a par value of US$0.001 will automatically combine and convert into one issued and outstanding share of common stock with the same par value of US$0.001. The reverse split will affect all stockholders uniformly and will not alter any stockholder's percentage ownership interest in the Company, except for minimal changes that may result from the treatment of fractional shares. No action is required by stockholders holding their shares through a brokerage account.

No fractional shares will be issued to any stockholders in connection with the reverse split, and each stockholder will be entitled to receive one full share of common stock in the Company in lieu of the fractional share that would have resulted from the reverse split.

At the time the share consolidation is effective, the Company's total issued and outstanding common shares will change from 27,290,710 common shares to approximately 1,364,536 common shares. The Company's authorized shares will remain unchanged.

**About Advanced Biomed Inc.** 

Advanced Biomed Inc. is a Nevada corporation specializing in innovative biomedical technologies for cancer detection and precision medicine.

Operating through the subsidiary in Taiwan, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion.

For more information, please visit: www.advanbiomed.com.

**Forward-Looking Statements** 

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the documents filed with the United States Securities and Exchange Commission (the "SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

**For more information, please contact:**

Advanced Biomed Inc.

Steven I-Fang Cheng

Email: info@advbiomedicine.com

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;invest@advbiomedicine.com

## Exhibit 3.1

**Exhibit 3.1**

![](ea027844801_ex3-1img1.jpg)

Business Number E16138432021 - 9 Filed in the Office of Secretary of State State Of Nevada Filing Number 20265497613 Filed On 2/3/2026 10:33:00 AM Number of Pages 3

![](ea027844801_ex3-1img2.jpg)

Profit Corporation: Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390) Certificate to Accompany Restated Articles or Amended and Restated Articles ‹PURSUANT TO NRS 78 403) Officer's Statement (PURSUANT TO NRS 80.030) Date: 02/13/2026 Time. 1am (must not be later than 90 days after the certificate is filed) 4. Effective Date and Time: (Optional) Changes to tahes the following effect: The entity name has been amended. The registered agent has been changed. (attach Certificate of Acceptance from new registered agent) The purpose of the entity has been amended. The authorized shares have been amended. The directors, managers or general partners have been amended. IRS tax language has been added Articles have been added. Articles have been deleted. Other. The articles have been amended as follows. (provide article numbers, if available) See additional page attached (attach additional page(s) if necessary) 5. Information Being Changed: (Domestic corporations only) \*" " Chief Executive Officer Signature of Officer or Authorized Signer Title Signature of Officer or Authorized Signer Title \*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each clars or series affected by the amendment regardless tc limitations or restrirtionr en the vcting power thereof. 6. Signature: (Required) Please include any required or optional information in space below: (attach additional page(s) if necessary) Article VI shall be amended to add the following section: Section 3. Effective on February 13, 2026, every twenty (20) outstanding shares of common stock with a par value of $0.001 per share shall without further action by the Corporation or the holder thereof be combined into and automatically become one share of common stock with a par value of $0.001 per share (the "Reverse Split"); provided, however, no fractional shares of common stock shall be issued in connection with the Reverse Split, and instead, the Corporation shall issue one full share of post - Reverse Split common stock to any stockholder who...(See full text in the additional page) 4 0 33 : 59 a . m . 02 — 03 - 2026 \| 6 18886118813 Page: 6 of 7 2026 - 02 - 03 18:33:47 GMT FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada 89701 - 4201 (775) 684 - 5708 Website: www.nvsos.gov 18886118813 From: Vcorp Services, LI This form must be accompanied by appropriate fees. Page z of y Revised: 9/1/2023

![](ea027844801_ex3-1img3.jpg)

10:33:59 a. m. 02 — 03 — 2026 7 18886118813 To: Pa B e: 7 of 7 2026 - 02 - 03 18:33:47 GMT Article VI shall be amended to add the following section: Section 3. Effective on £ ebruary 13 . 2 tJ 26 , every twenty (2 U) outstanding shares of common stock with a par value of $0 . 001 per sharc shall without turthcr action by the Corporation or the holder thereof be combined into and automatically become one share of common stock with a par value or' $0 . 001 per share (the "Reverse Split") : provided, however, no fractional shares of" common stock shall be issued in connection with the Reverse Split . and instead, the Corporation shall issue one trill share of" post - Rcverse Split coiiiinon stock to any stockholder who would have been entitled to receive a fractional share of common stock as a result of thc Reverse Split . 18886118813 From: Vcorp Services, LL

![](ea027844801_ex3-1img4.jpg)

NEVADA STATE BUSINESS LICENSE ADVANCED BIOMED INC Nevada Business Identification # NV20212175095 Expiration Date: 07/31/2026 In accordance with Title 7 of Nevada Revised Statutes, pursuant to proper application duly filed and payment of appropriate prescribed fees, the above named is hereby granted a Nevada State Business License for business activities conducted within the State of Nevada . Valid until the expiration date listed unless suspended, revoked or cancelled in accordance with the provisions in Nevada Revised Statutes. License is not transferable and is not in lieu of any local business license, permit or registration. License must be cancelled on or before its expiration date if business activity ceases. Failure to do so will result in late fees or penalties which, by law, cannot be waived . Certificate Number: B202602036466510 You may verify this certificate online at https://www.nvsilverflume.gov/home IN WITNESS WHEREOF, I have hereunto set my hand and affixed the Great Seal of State, at my office on 02/03/2026. FRANCISCO V. AGUILAR Secretary of State